Data reported from the AxisBiotix-Ps™ food supplement consumer study has shown highly positive results in psoriatic participants. The psoriatic participants who completed the study reported substantial reductions in itchiness, redness, irritability, and flaky skin.

The AxisBiotix-Ps™ study, which commenced in February 2021, was a 56 day ‘self-managed’ consumer study with 177 participants self-identifying as suffering from ‘mild to moderate’ psoriasis. The 91 participants from this group that completed the study reported the following results:

• 76% reported that their skin felt less itchy;
• 75% reported that their skin appeared less red;
• 73% reported that their skin felt less irritable;
• 65% reported that they had fewer ‘flaky patches’ of skin.

Participants who responded positively about their skin health, also reported positive changes to their lifestyle. On average, at day 56:

• 62% reported having more energy
• 64% reported better sleep
• 66% reported positive changes to their general mood.

Professor Cath O’Neill, Chief Scientific Officer at SkinBioTherapeutics and Professor of Translational Dermatology at the University of Manchester, said, “The results have exceeded our expectations, with improvements across all the key markers for irritable skin conditions like psoriasis – from skin itchiness to redness and number of flaky patches.”

She continued, “We have also received highly positive feedback from participants about improvements to their sense of wellbeing, such as being able to sleep better and pursuing activities they enjoyed before, such as painting and long walks, even wearing shorts, which they had given up because of their condition.”

AxisBiotix-Ps™, a powdered supplement made up of a novel blend of bacterial strains, has been specifically designed to modulate the immune system, by harnessing the gut-skin axis, to address problems associated with sensitive skin conditions, such as psoriasis. AxisBiotix-Ps™ has been developed through a partnership with Winclove Probiotics B.V. in response to the growing body of research highlighting the relationship between the gut and the skin, and scientific evidence pointing to a link between gut dysfunction, stress-induced alterations to the gut microbiome and skin inflammation.

Psoriasis is a debilitating skin condition caused by a malfunction of the immune system whereby raised ‘plaques’ form on the skin, which can be flaky, scaly and itchy. The condition is common, with approximately 2-3% of the global population believed to suffer from it. There is currently no cure; therapies tend to be steroid-based, which cannot be used long term and have side effects. Although there have been some recent treatment breakthroughs, these systemic treatments are usually only available to people with severe psoriasis which has not responded to other medications due to their potentially serious side effects.

Following the highly positive results from the AxisBiotix-Ps™ food supplement consumer study SkinBioTherapeutics, through its subsidiary, AxisBiotix, is targeting a commercial launch of the product in Q4 2021. The product will be sold on a monthly subscription basis.

AxisBiotix will be seeking approval for the product as a food supplement in the UK, US and Europe, with the intention to launch within these regions post approval.

Interested parties are asked to pre-register for the product prior to its launch at www.axisbiotix.com.